Menu

AbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition

Article |

indigohawk 7d ago
AbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition

AbbVie has agreed to help finance a KRAS inhibitor from Kestrel Therapeutics in a deal that could end with the pharma buying the company outright.

Comments (0)

Newest

No comments yet.